Anaplastic Plasmacytoma - 139 Studies Found Completed : Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma : Multiple Myeloma and Plasma Cell Neoplasm : 1999-11-01 : Drug: dexamethasone Drug: doxorubicin hydr Completed : Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma : Multiple Myeloma and Plasma Cell Neoplasm : 1999-11-01 : Drug: carmustine Drug: cyclophosphamide Completed : High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse : Multiple Myeloma and Plasma Cell Neoplasm : 1999-11-01 : Biological: filgrastim Drug: cyclophospham Completed : Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma : Multiple Myeloma and Plasma Cell Neoplasm : 1999-11-01 : Biological: filgrastim Biological: recombi Completed : SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant : Lymphoma Multiple Myeloma and Plasma Cell Neoplasm : 1999-11-01 : Biological: bleomycin sulfate Completed : Beta Alethine in Treating Patients With Myeloma : Multiple Myeloma and Plasma Cell Neoplasm Precancerous Condition : 2000-11-06 : Drug: beta alethine Completed : Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting : Multiple Myeloma : 2013-09-17 : Drug: Pomalidomide Other Name: Completed : Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma : Multiple Myeloma : 2010-09-09 : Drug: CX-4945 CX-4945 capsules, administered orally,as escalating doses. Dose schedule: four times daily Active, not recruiting : Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma : Multiple Myeloma and Plasma Cell Neoplasm Neurotoxicity : 2008-11-14 : Drug: bortezomib Given IV Terminated : Studying Common Genetic Mutations Related to Mucositis in Patients With Multiple Myeloma Receiving High-Dose Melphalan : Mucositis Multiple Myeloma and Plasma Cell Neoplasm : 2008-01-22 : Other: laboratory biomarker analysis Blood or cheek cells wil be collected. <<< Previous | Next >>>
